Signant Health: consider DCT design factors from the start
While the pandemic saw many trials to shift to decentralized midstream, an expert from the trial tech firm suggests a ground-up design approach is preferable.
Stay updated with breaking news from Bill Byrom. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
While the pandemic saw many trials to shift to decentralized midstream, an expert from the trial tech firm suggests a ground-up design approach is preferable.
Toronto, ON (PRWEB) October 14, 2021 -- In June 2021, the US FDA issued draft guidance entitled, “Core Patient-Reported Outcomes in Cancer Trials,” to provide
Scaling Up eConsent in Traditional and Decentralized Clinical Trials (DCTs), Upcoming Webinar Hosted by Xtalks Share Article In this free webinar, industry experts will discuss the basics of eConsent, provide recommendations to adapt current workflows to modernize with eConsent, as well as outline best practices for managing electronic consent/reconsent on a global scale. Youwill also learn the optimization benefits of integrating eConsent with eClinical tools/applications throughAstraZeneca’s experience using eConsent within their eClinical technology infrastructure. Whether you are curiou...